Tyra Biosciences announced initial Phase 2 trial results for its oral drug dabogratinib targeting bladder cancer, reporting a favorable safety profile but notable adverse events in some patients. Following this, the company's stock price fell 17.66% on September 9, 2026. Pomerantz LLP has launched an investigation into whether Tyra and its executives engaged in securities fraud or unlawful practices related to this announcement. Investors affected by the stock drop are encouraged to contact the law firm for potential class action participation.
KeyBanc initiated coverage on Air Products and Chemicals with a 'Sector Weight' rating, signaling expected performance in line with its sector. Despite the neutral outlook, the company showed strong profitability with a 110 basis point rise in adjust...
RH reported strong Q2 financial results, with earnings per share of $2.70 far exceeding analyst estimates of $0.38 and revenue of $922.20 million beating the $915.09 million forecast. This performance comes despite a recent 25% drop in RH's stock pri...
Tenon Medical's stock surged 116% after repaying $5.16 million in convertible debt, removing dilution risk for shareholders. Wealthfront also rose 15% following strong quarterly earnings that beat expectations. Digital Brands Group and PicoCELA saw s...
Bitcoin's price outlook is bullish as strong inflows into U.S. spot bitcoin ETFs, totaling over $600 million in early September, support a recovery above $80,000. Producer Price Index data showed slightly higher inflation, but markets had anticipated...
Skyworks Solutions CEO Phil Brace confirmed at the Goldman Sachs Communacopia & Technology Conference that the company is in the final stages of closing its merger with Qorvo. The deal is expected to close within the current fiscal year after success...
